相关临床试验
176
20 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1388
进行中（未招募）
13
7.4%
已完成
72
40.9%
尚未招募
7
4.0%
招募中
43
24.4%
暂停
2
1.1%
终止
7
4.0%
Unknown
25
14.2%
撤回
7
4.0%
暂无批准数据
- iMDx's digital PCR-based GraftAssureIQ test demonstrated equivalent donor-derived cell-free DNA measurements compared to next-generation sequencing platforms in a head-to-head study of 96 kidney transplant recipients. - The University Hospital Heidelberg study represents the first direct comparison of two commercially available dd-cfDNA test kits based on single nucleotide polymorphisms, with digital PCR showing improved analytical sensitivity for detecting low-quantity dd-cfDNA. - Results support iMDx's preparation for commercial launch following expected regulatory approval next year, targeting the estimated $1 billion transplant rejection testing market. - Extended study data will be presented at the European Society of Organ Transplantation Congress in London from June 29 to July 2, 2025.
- Phase 3 GMMG ReLApsE trial reveals salvage transplantation plus lenalidomide/dexamethasone did not significantly improve survival compared to lenalidomide/dexamethasone alone in relapsed multiple myeloma patients. - With median follow-up of 99 months, overall survival was 67.1 months in transplant arm versus 62.7 months in control arm, showing no statistically significant difference (P = .44). - Study included 282 patients across 16 German sites, demonstrating consistent results across key subgroups regardless of factors like age, disease staging, and cytogenetic risk status.
- HDP-101, a novel BCMA-targeting antibody-drug conjugate, demonstrates encouraging efficacy in heavily pretreated multiple myeloma patients. - The phase 1/2a trial (HDP-101-01) evaluated HDP-101 in patients with progressive or refractory multiple myeloma, showcasing manageable toxicity. - Preliminary data revealed partial responses and stable disease in several patients, particularly in the 100 μg/kg dose cohort. - HDP-101's unique amanitin payload overcomes drug resistance and targets cells with low BCMA expression, offering a new therapeutic avenue.
